← Back to headlines
New Drug Class Approved in Europe for Multiple Sclerosis
Europe has approved the first BTK enzyme inhibitor, a new class of drugs designed to slow the progression of multiple sclerosis by mitigating the immune system's attack on neurons.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
